Related Experiment Video
Updated: Jun 5, 2026
05:08
Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
Published on: October 3, 2019
Evolving concepts concerning cardiac β-adrenoceptor function in heart failure.
Black James1, Fitzgerald Desmond
1Materia Medica, Mere Croft Chester Road, Mere Cheshire WA16 6LG, UK.
Current Pharmaceutical Design
|January 21, 2011
Summary
Beta-adrenergic blocking drugs are used in heart failure treatment. This review examines their clinical use, focusing on the risks of excessive beta-2 adrenergic receptor (β(2)-AR) activation and the benefits of selective β(2)-AR antagonists.
Area of Science:
- Cardiology
- Pharmacology
- Heart Failure Research
Background:
- Congestive heart failure (CHF) management involves beta-adrenergic blocking drugs.
- The pharmacological profiles of these drugs impact clinical outcomes.
- Excessive beta-2 adrenergic receptor (β(2)-AR) activation can have undesirable effects.
Purpose of the Study:
- To review the historical and current clinical application of beta-adrenergic blocking drugs in CHF.
- To explore the relationship between drug properties and patient outcomes.
- To discuss the rationale for using selective β(2)-AR antagonists in heart failure.
Main Methods:
- Literature review of clinical studies on beta-blockers in heart failure.
- Analysis of pharmacological properties and their correlation with clinical outcomes.
- Discussion of the theoretical basis for selective β(2)-AR antagonism.
Main Results:
- Beta-blockers have evolved in their application for CHF.
- Specific drug properties influence therapeutic efficacy and adverse events.
- Concerns exist regarding over-activation of β(2)-AR.
Conclusions:
- The optimal profile for beta-blockers in CHF requires careful consideration of receptor selectivity.
- Selective β(2)-AR antagonists may offer a more targeted approach to managing heart failure.
- Further research into specific β(2)-AR antagonism is warranted for CHF treatment.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...